Why the study?
Does rofecoxib increase the risk of serious coronary heart disease in patients aged 18-84 years?
Does rofecoxib increase the risk of serious coronary heart disease in patients aged 18-84 years?
Rofecoxib use was associated with a substantial number of excess cases of serious coronary heart disease, supporting its withdrawal from the market.
Answers are grounded in this paper and cite their sources.
Rofecoxib was associated with excess serious CHD; leaves open precise risk attribution without randomized confirmation.
The COX 2 (cyclo-oxygenase-2) inhibitor rofecoxib (Vioxx) could have caused an estimated 88 000-140 000 excess cases of serious coronary heart disease in the United States since its launch in 1999, says a study published this week. The drug was withdrawn in September last year after being linked to increased cardiac deaths ( BMJ 2004;329: 816). The study analysed a cohort of all patients age 18-84 years receiving health care from a managed care organisation, Kaiser Permanente, in California, who were treated with …
No takes yet. Share an insight, caveat, or question.
Susan Mayor (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: